| Literature DB >> 34769660 |
Blake Langenbach1, Mark Wilson1.
Abstract
Per- and polyfluoroalkyl substances (PFAS) are an emerging environmental crisis. Deemed forever chemicals, many congeners bioaccumulate and are incredibly persistent in the environment due to the presence of the strong carbon-fluorine covalent bonds. Notable PFAS compounds include perfluorooctanesulfonic acid (PFOS), perfluorooctanoic acid (PFOA), and GenX. Robust toxicological knowledge exists for these substances, but regulatory decisions based on this knowledge has fallen behind. The United States Environmental Protection Agency (EPA) has addressed this issue with the PFAS Action Plan and EPA Council on PFAS, but the regulatory framework is severely lacking. Currently, no federal regulations or standards exist. Many occupational and non-occupational human cohorts exist that can lend knowledge on the environmental implications of PFAS and associated health effects. Occupationally, firefighters face significant exposure risks due to use of PFAS containing aqueous film-forming foams (AFFFs) and personal protective equipment contamination. Non-occupationally, wastewater discharge in North Carolina led to chronic and widespread residential exposure to GenX via drinking water contamination. This public health review seeks to convey the current and future significance of PFAS as an environmental contaminate, to lend considerations on regulatory frameworks within the USA, and to help guide and promote the need for future epidemiological studies in order to tackle this environmental emergency. While the PFAS Action Plan creates a scientific and regulatory foundation, it is important to take these lessons and apply them to future environmental health issues.Entities:
Keywords: AFFFs; Chemours; GenX; PFAS; hexafluoropropylene oxide-dimer acid (HFPO-DA); perfluoroalkyl; perfluorooctanesulfonic acid (PFOS); perfluorooctanoic acid (PFOA); polyfluoroalkyl
Mesh:
Substances:
Year: 2021 PMID: 34769660 PMCID: PMC8583519 DOI: 10.3390/ijerph182111142
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
ATSDR General Health Outcomes and Effects among PFOA, PFOS, and 12 other PFAS.
| Effects | Health Outcomes [ |
|---|---|
| Hepatic: | Increased serum enzymes, decreased serum bilirubin |
| Cardiovascular: | Pregnancy-induced hypertension and/or pre-eclampsia |
| Endocrine: | Increased risk of thyroid disease |
| Immune: | Increased risk of asthma diagnosis, decreased antibody response to vaccine |
| Reproductive: | Increased risk of decreased fertility |
| Developmental: | Small decreases in birth weight |
Adapted from ATSDR 2018 [4].
Summary of U.S. Environmental Protection Agency’s (EPA) Regulatory Framework [5].
| EPA Regulatory Framework | Summary of Regulation [ |
|---|---|
| PFOA Stewardship | 8 leading North American companies achieved a 95% reduction of PFOA + PFOA-related chemicals by 2015 |
| Safe Drinking Water Act (SDWA) | No established maximum contaminant levels (MCLs) |
| Fifth Unregulated | Requires sampling of lithium + 29 various PFAS between 2023 and 2025 |
| Toxic Substances | 294 PFAS reviewed, 191 regulated through orders and Significant New Use Rules (SNURs) |
| Comprehensive | PFAS currently not listed as hazardous substances |
| Resource Conservation and Recovery Act (RCRA) | Primary remediation goal of 70 parts per trillion |
| Clean Air Act (CAA) | No published non-cancer reference concentrations for inhalation exposure for PFOS or PFOA |
| Toxicity Assessments | Perfluorobutane Sulfonic Acid (PFBS) assessment not published due to political interference and scientific integrity violations |
ATSDR’s Oral Minimal Risk Levels (MRLs) and Human Equivalent Doses for Various PFAS.
| PFAS | Oral MRL (mg/kg/day) | Human Equivalent Dose (mg/kg/day) |
|---|---|---|
| PFOA | 3 × 10−6 | 0.00821 at the LOAEL |
| PFOS | 2 × 10−6 | 0.000515 at the NOAEL |
| PFHxS | 2 × 10−5 | 0.0047 at the NOAEL |
| PFNA | 3 × 10−6 | 0.001 at the NOAEL |
Adapted from ATSDR (2018) [4].
Hazard Summary of GenX Chemicals in Rat and Mice Studies.
| Effects | Health Outcomes |
|---|---|
| Hepatic: | Hepatocellular hypertrophy, increased liver-to-bodyweight ratio |
| Hematological: | Decreases in red blood cell count, hemoglobin, and red blood cell percentage in blood |
| Renal: | Kidney hypertrophy and blood urea nitrogen in female rats |
| Developmental/ | Decreased mouse pup weight, delays in balanopreputial separation and vaginal patency |
| Immunological: | Decreased serum globulin levels and spleen weight in female mice |
| Cancer: | Increased incidence of liver tumors (females) and combined pancreatic acinar adenomas and carcinomas (males) |
Adapted from USEPA (2018) [74].